Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
McKesson
Express Scripts
Colorcon
McKinsey

Last Updated: May 20, 2022

Pegfilgrastim - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for pegfilgrastim

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Hospital Universitario Dr. Jose E. GonzalezPhase 2
Canadian Cancer Trials GroupPhase 3
TakedaPhase 3

See all pegfilgrastim clinical trials

Pharmacology for pegfilgrastim
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pegfilgrastim Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pegfilgrastim Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Amgen, Inc. NEULASTA pegfilgrastim Injection 125031 See Plans and Pricing 2013-12-03 Company disclosures
Amgen, Inc. NEULASTA pegfilgrastim Injection 125031 See Plans and Pricing 2013-12-10 Company disclosures
Amgen, Inc. NEULASTA pegfilgrastim Injection 125031 See Plans and Pricing 2039-02-26 Company disclosures
Amgen, Inc. NEULASTA ONPRO pegfilgrastim Injection 125031 See Plans and Pricing 2013-12-03 Company disclosures
Amgen, Inc. NEULASTA ONPRO pegfilgrastim Injection 125031 See Plans and Pricing 2013-12-10 Company disclosures
Amgen, Inc. NEULASTA ONPRO pegfilgrastim Injection 125031 See Plans and Pricing 2039-02-26 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for pegfilgrastim Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for pegfilgrastim

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C300106 Netherlands See Plans and Pricing PRODUCT NAME: PEGFILGRASTIM; NAT. REGISTRATION NO/DATE: EU/1/02/228/001 20020822; FIRST REGISTRATION: EU/1/02/228/001 20020822
SPC/GB14/009 United Kingdom See Plans and Pricing PRODUCT NAME: LIPEGFILGRASTIM; REGISTERED: UK EU/1/13/856/001 20130729
336 5002-2014 Slovakia See Plans and Pricing PRODUCT NAME: LIPEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/13/856 20130729
CA 2014 00004 Denmark See Plans and Pricing PRODUCT NAME: LIPEGFILGRASTIM, HERUNDER METHOXYPOLYETHYLENGLYCOL KONJUGAT; REG. NO/DATE: EU/1/13/856 20130725
4/2014 Austria See Plans and Pricing PRODUCT NAME: LIPEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/13/856 20130725
SZ 5/2003 Austria See Plans and Pricing PRODUCT NAME: PEGFILGRASTIM
5/2003 Austria See Plans and Pricing PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/228/001 20020822
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Moodys
Merck
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.